Team:Washington/Gram Positive/Test

From 2010.igem.org

(Difference between revisions)
(Results: Data Analysis)
Line 26: Line 26:
'''More descriptive titles, verification that your CapD_CP was a monomer ( gel) should go before testing catalytic ability'''
'''More descriptive titles, verification that your CapD_CP was a monomer ( gel) should go before testing catalytic ability'''
 +
=Construction of CapD_CP=
 +
==CapD_CP runs on a gel as one clean band==
 +
Depicted in Figure X is a gel comparing purified capD and capD_cp.  This demonstrates one of the major advantages of CapD_CP, in addition to the fact that it is easy to express, it comes out in 1 clean band and is easy to quantify.  CapD shows three bands, while the lower two bands are the expected pieces that occur after the enzyme undergoes self cleavage, the upper band is of unclear origin.  It's mass corresponds to what would either be the unprocessed, inactive, monomeric form of the enzymes or the dimeric form that didn't denature.  This ambiguity makes the amount of active enzyme from capD difficult to quantify.
-
==Why CapD_CP?==
+
[[Image:CapDandCapDCPGell.jpg|480px|left|thumb|'''Figure 1.  CapD_CP as expected.  Right: CapD has ambiguous bands, making quantifying difficult and assaying protein activity less accurate
-
==Easy Quantification==
+
''']]
-
[[Image:CapDandCapDCPGell.jpg|thumb|400px|right| CapD_CP as expected.  Right: CapD has ambiguous bands, making quantifying difficult and assaying protein activity less accurate]]
+
<br style="clear: both" />
-
In addition to the fact that CapD_CP is easy to express, it has one more crucial advantage over CapD.  When purifying CapD_CP, given our mass spec data, we can assume a massive majority of the purified CapD_CP is functional.  CapD, however, is a much more ambiguous case, as illustrated by our protein gel results.  The lower two bands of CapD correspond to the two subunits of cleaved CapD, which are active.  The upper band may be uncleaved, therefore unfunctional, CapD, or dimeric, active CapD that simply did not denature, or a combination of both.  Because of this, its difficult to quantify how much active protein is in a solution of purified CapD, making assaying activity a nightmare.  For this reason, we made our active site mutations to CapD_CP.
+
-
[[Image:CapDCP_MassSpecNoMethionine.png|thumb|780px|right| Expected weight of CapD_CP without Methionine=55285Da, with Methionine=55417Da. Our mass spec detected a peak at 55274.8Da (no Methionine) well within the 0.02% error limit for our mass spec]]
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
==Unchanged Properties==
+
==CapD_CP is produced without the N-term methionine as expected==
-
[[Image:Washington_CapD_CapD_CP.jpg|thumb|450px|left|]]
+
In Figure X we show the mass spec conformation of the molecular wieght of capD_cp.  As expected the N-terminal methionine is cleaved off by the native E. coli methionine aminopeptidase, resulting in a high level of pure active enzyme.
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
=='''Test: Enzyme Assay'''==
+
[[Image:CapDCP_MassSpecNoMethionine.png|600px|left|thumb|''' Figure 2.  Expected weight of CapD_CP without Methionine=55285Da, with Methionine=55417Da. Our mass spec detected a peak at 55274.8Da (no Methionine) well within the 0.02% error limit for our mass spec''']]
 +
<br style="clear: both" />
-
[[Image:Washington_Assay_Scheme_revised2.jpg|thumb|400px|left|The general scheme of our fluorescence-based [https://2010.igem.org/Team:Washington/Protocols/EnzymeAssayCapD enzyme assay]]]
+
==The circular permutation didn't result in a loss of activity==
-
After we have the CapD_CP mutants, we tested our mutants for their catalytic activity using our fluorescence-based enzyme assay scheme. Fluorescence-based enzyme assay measures the rate at which fluorescence in the testing media is released and the amount fluorescence depends on the rate at which fluorophore-quencher linkage is disrupted. Our substrate PDGA contains a linked fluorophore-quencher component. The faster fluorophore-quencher component is cleaved, the higher the amount of fluorescence is released and thus the greater the enzymatic activity observed.
+
In Table X we show the kinetic paramters for capD and capD_cp as determined using our enzyme assay (link). While the kcat is difficult to quantify for capD the data suggests that the kinetic parameters are within error of eachother. Therefore the circullar permutation of capD did not have a negative effect on catalytic actiivty, suggesting that the autoprocessing feature is not required for catalysis but simply a regulatory function for the protein.
-
=='''Results: Data Analysis'''==
+
[[Image:Washington_CapD_CapD_CP.jpg|thumb|400px|left| '''Kinetic properties determined for a Michaelis-Menton profile of capD_cp and capD, as described in our enzyme assay protocols section.''']]
-
===Validating CapD_CP Activity===
+
<br style="clear: both" />
 +
 
 +
 
 +
==Catalytic Residue knock-outs show that capD_cp is catalyzing the reaction as expected==
Before we can predict which mutations increase hydrolysis capability, we need to validate that the circularly permuted version of CapD has measurable activity for further assessments. We also hypothesize a threonine residue in the catalytic site of CapD_CP plays an important role in the catalysis reaction and mutating it will eliminate all enzymatic activity. Thus we created two mutants, T2V and T2A, to act as negative controls. The result (figure 1 below) of this assay confirms our hypothesis that CapD_CP has enzymatic activity to the two catalytic knockouts. The relatively flat activity curves of the knockout mutants confirm the hypothesis of the threonine's role in the catalytic site.  
Before we can predict which mutations increase hydrolysis capability, we need to validate that the circularly permuted version of CapD has measurable activity for further assessments. We also hypothesize a threonine residue in the catalytic site of CapD_CP plays an important role in the catalysis reaction and mutating it will eliminate all enzymatic activity. Thus we created two mutants, T2V and T2A, to act as negative controls. The result (figure 1 below) of this assay confirms our hypothesis that CapD_CP has enzymatic activity to the two catalytic knockouts. The relatively flat activity curves of the knockout mutants confirm the hypothesis of the threonine's role in the catalytic site.  
[[Image:Washington_Confirming_CP_activity_revised6.jpg|thumb|750px|left|Figure 1: Confirming the activity of CapD_CP by comparing it to two CapD_CP knockouts, T2A and T2V.different graphic is coming]]
[[Image:Washington_Confirming_CP_activity_revised6.jpg|thumb|750px|left|Figure 1: Confirming the activity of CapD_CP by comparing it to two CapD_CP knockouts, T2A and T2V.different graphic is coming]]
-
 
+
<br style="clear: both" />
-
=='''Analyzing CapD_CP'''==
+
-
 
+
-
[[Image:Washington_CapD_CP_Trans_Hydro_Kinectic_Table_full.jpg|thumb|400px|right|Figure 4 shows the kinetic constants of CapD_CP's transpeptidation and hydrolysis capability]]
+
-
 
+
-
[[Image:Washington_CapD_CP_Michaelis_Curve.jpg|thumb|300px|right|]]
+
-
 
+
-
The two abilities of CapD_CP are transpeptidation and hydrolysis. Based on the Kcat and Km (see figure 4)
+
-
values of the two, we conclude that CapD_CP is a weak binder and efficient catalyst for the transpeptidation reaction. In terms of  hydrolysis, it shows strong binding but slow catalysis, thus our mutant designs focus on increasing the catalytic efficiency.
+
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
<br />
 
-
=='''Mutant Designs'''==
+
=''Mutant Designs''=
By standardizing the activity slope of each design relative to CapD_CP, a scatterplot easily portrays the qualities of each mutant. Several designs show negative catalytic curves similar to the catalytic knockouts. Some immediately show a negative activity curve meaning decrease in transpeptidation, hydrolysis, or both. T20S is a promising mutant hydrolase design.
By standardizing the activity slope of each design relative to CapD_CP, a scatterplot easily portrays the qualities of each mutant. Several designs show negative catalytic curves similar to the catalytic knockouts. Some immediately show a negative activity curve meaning decrease in transpeptidation, hydrolysis, or both. T20S is a promising mutant hydrolase design.

Revision as of 18:31, 6 October 2010

More descriptive titles, verification that your CapD_CP was a monomer ( gel) should go before testing catalytic ability

Contents

Construction of CapD_CP

CapD_CP runs on a gel as one clean band

Depicted in Figure X is a gel comparing purified capD and capD_cp. This demonstrates one of the major advantages of CapD_CP, in addition to the fact that it is easy to express, it comes out in 1 clean band and is easy to quantify. CapD shows three bands, while the lower two bands are the expected pieces that occur after the enzyme undergoes self cleavage, the upper band is of unclear origin. It's mass corresponds to what would either be the unprocessed, inactive, monomeric form of the enzymes or the dimeric form that didn't denature. This ambiguity makes the amount of active enzyme from capD difficult to quantify.

Figure 1. CapD_CP as expected. Right: CapD has ambiguous bands, making quantifying difficult and assaying protein activity less accurate



CapD_CP is produced without the N-term methionine as expected

In Figure X we show the mass spec conformation of the molecular wieght of capD_cp. As expected the N-terminal methionine is cleaved off by the native E. coli methionine aminopeptidase, resulting in a high level of pure active enzyme.


Figure 2. Expected weight of CapD_CP without Methionine=55285Da, with Methionine=55417Da. Our mass spec detected a peak at 55274.8Da (no Methionine) well within the 0.02% error limit for our mass spec


The circular permutation didn't result in a loss of activity

In Table X we show the kinetic paramters for capD and capD_cp as determined using our enzyme assay (link). While the kcat is difficult to quantify for capD the data suggests that the kinetic parameters are within error of eachother. Therefore the circullar permutation of capD did not have a negative effect on catalytic actiivty, suggesting that the autoprocessing feature is not required for catalysis but simply a regulatory function for the protein.

Kinetic properties determined for a Michaelis-Menton profile of capD_cp and capD, as described in our enzyme assay protocols section.



Catalytic Residue knock-outs show that capD_cp is catalyzing the reaction as expected

Before we can predict which mutations increase hydrolysis capability, we need to validate that the circularly permuted version of CapD has measurable activity for further assessments. We also hypothesize a threonine residue in the catalytic site of CapD_CP plays an important role in the catalysis reaction and mutating it will eliminate all enzymatic activity. Thus we created two mutants, T2V and T2A, to act as negative controls. The result (figure 1 below) of this assay confirms our hypothesis that CapD_CP has enzymatic activity to the two catalytic knockouts. The relatively flat activity curves of the knockout mutants confirm the hypothesis of the threonine's role in the catalytic site.

Figure 1: Confirming the activity of CapD_CP by comparing it to two CapD_CP knockouts, T2A and T2V.different graphic is coming



Mutant Designs

By standardizing the activity slope of each design relative to CapD_CP, a scatterplot easily portrays the qualities of each mutant. Several designs show negative catalytic curves similar to the catalytic knockouts. Some immediately show a negative activity curve meaning decrease in transpeptidation, hydrolysis, or both. T20S is a promising mutant hydrolase design.

Washington Mutant design.jpg


Building the Gram(+) Therapeutic       Overview of Gram(-) Therapeutic